With a long history of clinical use, Chinese herbal medicine (CHM) is emerging as a
noticeable choice for its multi-level, multi-target and coordinated intervention effects against tumor.
Recently, many agents from CHM have shown powerful anti-angiogenic activities against tumor. In
this review, we discussed the anti-tumor angiogenic activities of 6 kinds of agents from CHM
(sulfated polysaccharides/glycopeptides, flavonoids, artemisinin, arsenic trioxide, ginsenoside, and
tanshinone). The underlying pharmacological mechanisms of cancer angiogenesis inhibition by these
agents are also gradually shown to us. Sulfated polysaccharides/glycopeptides and flavonoids may have synergistic effects
with targeted anti-angiogenic drugs mainly targeting VEGF pathway by inhibiting bFGF and HIF-1α pathway,
respectively. It is interesting that artemisinin and arsenic trioxide, two famous natural products worldwide, also have antitumor
activity at least in part via angiogenesis inhibition. In addition, some natural products that are widely used for
patients with cancer, such as ginseng and danshen, act as double-edged swords for tumor angiogenesis. Our review is
aimed at providing an understanding of anti-angiogenic compounds from CHM and we propose that these breakthrough
findings may have important implications for targeted-angiogenesis therapy and modernization of CHM.